Safety and Effectiveness of BPaL-Based Regimens to Treat Multidrug-Resistant TB: First Experience of an Italian Tuberculosis Referral Hospital

<b>Background/Objectives</b>: Tuberculosis (TB) is preventable and curable, but multidrug-resistant TB (MDR-TB) and extensively drug-resistant TB (XDR-TB) pose significant challenges worldwide due to the limited treatment options, lengths of therapies, and high rates of treatment failure...

Full description

Saved in:
Bibliographic Details
Main Authors: Gina Gualano, Maria Musso, Paola Mencarini, Silvia Mosti, Carlotta Cerva, Pietro Vittozzi, Antonio Mazzarelli, Angela Cannas, Assunta Navarra, Stefania Ianniello, Paolo Faccendini, Fabrizio Palmieri
Format: Article
Language:English
Published: MDPI AG 2024-12-01
Series:Antibiotics
Subjects:
Online Access:https://www.mdpi.com/2079-6382/14/1/7
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1832589337792872448
author Gina Gualano
Maria Musso
Paola Mencarini
Silvia Mosti
Carlotta Cerva
Pietro Vittozzi
Antonio Mazzarelli
Angela Cannas
Assunta Navarra
Stefania Ianniello
Paolo Faccendini
Fabrizio Palmieri
author_facet Gina Gualano
Maria Musso
Paola Mencarini
Silvia Mosti
Carlotta Cerva
Pietro Vittozzi
Antonio Mazzarelli
Angela Cannas
Assunta Navarra
Stefania Ianniello
Paolo Faccendini
Fabrizio Palmieri
author_sort Gina Gualano
collection DOAJ
description <b>Background/Objectives</b>: Tuberculosis (TB) is preventable and curable, but multidrug-resistant TB (MDR-TB) and extensively drug-resistant TB (XDR-TB) pose significant challenges worldwide due to the limited treatment options, lengths of therapies, and high rates of treatment failure. The management of MDR-TB has been revolutionized by all oral anti-TB drug regimens that are likely to improve adherence and treatment outcomes. These regimes include bedaquiline (B), pretomanid (P), and linezolid (L) (BPaL), and moxifloxacin if resistance to fluoroquinolones is not detected (BPaLM). Based on the evidence generated by the TB-PRACTECAL and ZeNix randomized controlled trials, BPaL/BPaLM regimens are recommended over the currently recommended longer regimens in patients with MDR-TB or monoresistance to rifampin (RR). To our knowledge, no data are currently available on the implementation of BPaL/BPaLM regimens in Italy. <b>Results</b>: Seventeen patients completed the BPaL/BPaLM regimen, with a treatment success rate of 90% (17/19), consistent with the literature data. Eleven patients out of the nineteen retained in care (58%) complained about symptoms consistent with adverse events (AEs). No treatment interruption was necessary due to AEs. <b>Methods</b>: Here, we report the real-world experience of a tertiary referral hospital for TB in Italy, from 2022 to 2024, in the management, outcomes, and adverse drug reactions of a cohort of twenty-two MDR/RR patients treated with BPaL and BPaLM regimens. <b>Conclusions</b>: BPaL-containing regimens also serve as promising options for patients with RR/MDR-TB in terms of real-life experience, but further multicentric studies are required in Europe to confirm the efficacy of shorter regimens to eliminate MDR TB.
format Article
id doaj-art-8204ef31bc074abdaee71d72266075be
institution Kabale University
issn 2079-6382
language English
publishDate 2024-12-01
publisher MDPI AG
record_format Article
series Antibiotics
spelling doaj-art-8204ef31bc074abdaee71d72266075be2025-01-24T13:18:29ZengMDPI AGAntibiotics2079-63822024-12-01141710.3390/antibiotics14010007Safety and Effectiveness of BPaL-Based Regimens to Treat Multidrug-Resistant TB: First Experience of an Italian Tuberculosis Referral HospitalGina Gualano0Maria Musso1Paola Mencarini2Silvia Mosti3Carlotta Cerva4Pietro Vittozzi5Antonio Mazzarelli6Angela Cannas7Assunta Navarra8Stefania Ianniello9Paolo Faccendini10Fabrizio Palmieri11Respiratory Infectious Diseases Unit, National Institute for Infectious Diseases “Lazzaro Spallanzani” IRCCS, 00149 Rome, ItalyRespiratory Infectious Diseases Unit, National Institute for Infectious Diseases “Lazzaro Spallanzani” IRCCS, 00149 Rome, ItalyRespiratory Infectious Diseases Unit, National Institute for Infectious Diseases “Lazzaro Spallanzani” IRCCS, 00149 Rome, ItalyRespiratory Infectious Diseases Unit, National Institute for Infectious Diseases “Lazzaro Spallanzani” IRCCS, 00149 Rome, ItalyRespiratory Infectious Diseases Unit, National Institute for Infectious Diseases “Lazzaro Spallanzani” IRCCS, 00149 Rome, ItalyRespiratory Infectious Diseases Unit, National Institute for Infectious Diseases “Lazzaro Spallanzani” IRCCS, 00149 Rome, ItalyDepartment of Microbiology, National Institute for Infectious Diseases “Lazzaro Spallanzani” IRCCS, 00149 Rome, ItalyDepartment of Microbiology, National Institute for Infectious Diseases “Lazzaro Spallanzani” IRCCS, 00149 Rome, ItalyDepartment of Epidemiology, National Institute for Infectious Diseases “Lazzaro Spallanzani” IRCCS, 00149 Rome, ItalyDiagnostic Imaging Unit for Infectious Diseases, National Institute for Infectious Diseases “Lazzaro Spallanzani” IRCCS, 00149 Rome, ItalyHospital Pharmacy, National Institute for Infectious Diseases “Lazzaro Spallanzani” IRCCS, 00149 Rome, ItalyRespiratory Infectious Diseases Unit, National Institute for Infectious Diseases “Lazzaro Spallanzani” IRCCS, 00149 Rome, Italy<b>Background/Objectives</b>: Tuberculosis (TB) is preventable and curable, but multidrug-resistant TB (MDR-TB) and extensively drug-resistant TB (XDR-TB) pose significant challenges worldwide due to the limited treatment options, lengths of therapies, and high rates of treatment failure. The management of MDR-TB has been revolutionized by all oral anti-TB drug regimens that are likely to improve adherence and treatment outcomes. These regimes include bedaquiline (B), pretomanid (P), and linezolid (L) (BPaL), and moxifloxacin if resistance to fluoroquinolones is not detected (BPaLM). Based on the evidence generated by the TB-PRACTECAL and ZeNix randomized controlled trials, BPaL/BPaLM regimens are recommended over the currently recommended longer regimens in patients with MDR-TB or monoresistance to rifampin (RR). To our knowledge, no data are currently available on the implementation of BPaL/BPaLM regimens in Italy. <b>Results</b>: Seventeen patients completed the BPaL/BPaLM regimen, with a treatment success rate of 90% (17/19), consistent with the literature data. Eleven patients out of the nineteen retained in care (58%) complained about symptoms consistent with adverse events (AEs). No treatment interruption was necessary due to AEs. <b>Methods</b>: Here, we report the real-world experience of a tertiary referral hospital for TB in Italy, from 2022 to 2024, in the management, outcomes, and adverse drug reactions of a cohort of twenty-two MDR/RR patients treated with BPaL and BPaLM regimens. <b>Conclusions</b>: BPaL-containing regimens also serve as promising options for patients with RR/MDR-TB in terms of real-life experience, but further multicentric studies are required in Europe to confirm the efficacy of shorter regimens to eliminate MDR TB.https://www.mdpi.com/2079-6382/14/1/7multidrug-resistant TBBPaL regimensItaly
spellingShingle Gina Gualano
Maria Musso
Paola Mencarini
Silvia Mosti
Carlotta Cerva
Pietro Vittozzi
Antonio Mazzarelli
Angela Cannas
Assunta Navarra
Stefania Ianniello
Paolo Faccendini
Fabrizio Palmieri
Safety and Effectiveness of BPaL-Based Regimens to Treat Multidrug-Resistant TB: First Experience of an Italian Tuberculosis Referral Hospital
Antibiotics
multidrug-resistant TB
BPaL regimens
Italy
title Safety and Effectiveness of BPaL-Based Regimens to Treat Multidrug-Resistant TB: First Experience of an Italian Tuberculosis Referral Hospital
title_full Safety and Effectiveness of BPaL-Based Regimens to Treat Multidrug-Resistant TB: First Experience of an Italian Tuberculosis Referral Hospital
title_fullStr Safety and Effectiveness of BPaL-Based Regimens to Treat Multidrug-Resistant TB: First Experience of an Italian Tuberculosis Referral Hospital
title_full_unstemmed Safety and Effectiveness of BPaL-Based Regimens to Treat Multidrug-Resistant TB: First Experience of an Italian Tuberculosis Referral Hospital
title_short Safety and Effectiveness of BPaL-Based Regimens to Treat Multidrug-Resistant TB: First Experience of an Italian Tuberculosis Referral Hospital
title_sort safety and effectiveness of bpal based regimens to treat multidrug resistant tb first experience of an italian tuberculosis referral hospital
topic multidrug-resistant TB
BPaL regimens
Italy
url https://www.mdpi.com/2079-6382/14/1/7
work_keys_str_mv AT ginagualano safetyandeffectivenessofbpalbasedregimenstotreatmultidrugresistanttbfirstexperienceofanitaliantuberculosisreferralhospital
AT mariamusso safetyandeffectivenessofbpalbasedregimenstotreatmultidrugresistanttbfirstexperienceofanitaliantuberculosisreferralhospital
AT paolamencarini safetyandeffectivenessofbpalbasedregimenstotreatmultidrugresistanttbfirstexperienceofanitaliantuberculosisreferralhospital
AT silviamosti safetyandeffectivenessofbpalbasedregimenstotreatmultidrugresistanttbfirstexperienceofanitaliantuberculosisreferralhospital
AT carlottacerva safetyandeffectivenessofbpalbasedregimenstotreatmultidrugresistanttbfirstexperienceofanitaliantuberculosisreferralhospital
AT pietrovittozzi safetyandeffectivenessofbpalbasedregimenstotreatmultidrugresistanttbfirstexperienceofanitaliantuberculosisreferralhospital
AT antoniomazzarelli safetyandeffectivenessofbpalbasedregimenstotreatmultidrugresistanttbfirstexperienceofanitaliantuberculosisreferralhospital
AT angelacannas safetyandeffectivenessofbpalbasedregimenstotreatmultidrugresistanttbfirstexperienceofanitaliantuberculosisreferralhospital
AT assuntanavarra safetyandeffectivenessofbpalbasedregimenstotreatmultidrugresistanttbfirstexperienceofanitaliantuberculosisreferralhospital
AT stefaniaianniello safetyandeffectivenessofbpalbasedregimenstotreatmultidrugresistanttbfirstexperienceofanitaliantuberculosisreferralhospital
AT paolofaccendini safetyandeffectivenessofbpalbasedregimenstotreatmultidrugresistanttbfirstexperienceofanitaliantuberculosisreferralhospital
AT fabriziopalmieri safetyandeffectivenessofbpalbasedregimenstotreatmultidrugresistanttbfirstexperienceofanitaliantuberculosisreferralhospital